Freeport, Bahamas, The, September 12, 2012 --(PR.com
)-- Matt Feshbach, CEO of Okyanos Heart Institute (http://www.okyanos.com/), which brings a new standard of care and a better quality of life to patients with coronary artery disease (CAD) using cardiac cell therapy, has announced that Chief Medical Officer Howard T. Walpole Jr., M.D., MBA, FACC, FACAI, FSCAI, presented at the Vanderbilt University Transition To Practice meeting on Aug. 14. His remarks were specifically directed to the fellows in the Division of Cardiology. A former Vanderbilt University medical resident and intern himself, Dr. Walpole shared his expert opinion on the outlook of current cardiology practices. Drawing upon both his medical and business backgrounds, Walpole emphasized the value of looking forward and thinking innovatively in an effort to adapt and thrive in the changing field of cardiology.
“It is Dr. Walpole’s extensive knowledge and experience in the medical field that makes him such an incredible cardiologist and someone on whom our institute can rely,” said Feshbach. “He is truly changing and improving lives with his approach to cardiology and cardiac treatments, and aspiring cardiologists can learn a great deal from him about today’s approaches to addressing the needs of the heart.”
“I am honored to share my experiences and be part of Vanderbilt’s Transition to Practice meeting,” said Walpole. “As a former medical resident and intern at Vanderbilt, it is exciting to see the growth the school has achieved and have the opportunity to present to the world’s future cardiologists my perspective on the current state and future of cardiology. As we work together to continue advancing the practice of medicine, we are sure to find new ways of approaching critical issues and meeting patients’ needs.”
New Media Content:
Okyanos LinkedIn page:
Okyanos Facebook page:
Okyanos Twitter page:
About Okyanos Heart Institute:
Based in Freeport, the Bahamas, the Okyanos Heart Institute is a Center of Excellence (CoE) adhering to U.S. surgical center standards and led by Chief Medical Officer Howard T. Walpole Jr., M.D., MBA, FACC, FACAI, FSCAI, a leader of the American College of Cardiology for many years. The mission of Okyanos Heart Institute is to bring a new standard of care and a better quality of life to patients with chronic coronary artery disease using cardiac cell therapy. The Okyanos treatment utilizes cardiac cell therapy, a unique blend of stem and regenerative cells to support the growth of new blood vessels and to assist the heart in repairing tissue damaged by heart attack and disease. The Greek god of rivers, “Okyanos” symbolizes the primary mechanism of action that these adult stem cells have on ischemic (lack of blood flow) heart tissue, the result of the plaque deposits in the coronary arteries. The stem cells, derived from a person’s adipose (fat) tissue, create new blood vessels, a process known as angiogenesis. These cells facilitate blood flow in the heart and intake and use of oxygen, as measured by a rigorous clinical trial known as the PRECISE trial, as well as cardiac cell therapy trials at leading research institutions. For more information, visit http://www.okyanos.com/.
MMI Public Relations